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ABSTRACT
Effective therapeutics exploit common characteristics shared amongst cancers. 
As many cancers present chromosomal instability (CIN), one possible approach to 
treat these cancers could be to increase their CIN above a threshold that would 
affect their viability. Here, we investigated whether causing polyploidy by cytokinesis 
failure could represent a useful approach. We show that cytokinesis failure caused 
by depletion of Citron kinase (CIT-K) dramatically decreased cell proliferation in 
breast, cervical and colorectal cancer cells. CIT-K depletion activated the Hippo tumor 
suppressor pathway in normal, but not in cancer cells, indicating that cancer cells 
have evolved mechanisms to bypass this control. CIT-K depleted cancer cells died via 
apoptosis in a caspase 7 dependent manner and, consistent with this, p53-deficient 
HCT116 colon carcinoma cells failed to induce apoptosis after cytokinesis failure. 
However, other p53-mutated cancer cells were able to initiate apoptosis, indicating 
that cytokinesis failure can trigger apoptosis through a p53-independent mechanism. 
Finally, we found that actively dividing and, in some cases, polyploid cancer cells 
were more susceptible to CIT-K depletion. In sum, our findings indicate that inducing 
cytokinesis failure could be a promising anti-cancer therapeutic approach for a 
wide range of cancers, especially those characterized by fast cell proliferation and 
polyploidy.
INTRODUCTION
Chromosomal instability (CIN) is a hallmark of 
many cancers [1]. CIN is characterized by recurrent 
chromosomal changes that contribute to tumorigenesis by 
altering the balance of critical growth and death pathways. 
Although its role in cancer onset is still debated, CIN has 
been implicated in cancer evolution, diversification and 
heterogeneity, is associated with poor clinical outcome 
and drug resistance, and has been suggested to play a 
role in the development of metastases [2-4]. CIN can be 
classified either as structural (alterations in chromosome 
structure, such as translocations, inversions, duplications, 
etc.) or numerical (alterations in chromosome numbers, 
i.e. aneuploidy and polyploidy), but they frequently occur 
together in many cancers. Many studies have focused on 
understanding the mechanisms that generate aneuploidy 
in order to shed light into the genesis of numerical CIN 
[5, 6]. It is becoming increasingly evident that polyploidy 
also plays an important role in promoting tumorigenesis, 
CIN and drug resistance, thus contributing to cancer 
evolution and clonal heterogeneity [7-9]. There have been 
suggestions that targeting CIN might be a useful approach 
for cancer treatment [10, 11] and one possible strategy 
could be to increase polyploidy by interfering with cell 
division in cancer cells above a threshold that would be 
incompatible with cell viability. Such a strategy would 
specifically target highly proliferating CIN cancer cells 
and thus be potentially less toxic for normal tissues.
With this hypothesis in mind, we have investigated 
whether causing polyploidy via cytokinesis failure could 
be a valid strategy in promoting cell death in cancer cells. 
To this aim, we decided to provoke cytokinesis failure by 
targeting the serine/threonine kinase citron kinase (CIT-K) 
for the following reasons. First, CIT-K is specifically 
required only during the late stages of cytokinesis for the 
organization and function of the midbody, an organelle 
required for the final separation, or abscission, of the two 
daughter cells [12-16]. This specific late mitotic function 
makes CIT-K an interesting target in the light of recent 
studies indicating that targeting post-metaphase events is 
a more effective cancer treatment than other anti-mitotic 
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agents [17, 18]. Second, CIT-K depletion by RNAi has 
already been shown to decrease proliferation of prostate 
and hepatocellular cancer cells and to inhibit tumor 
growth in xenograft mice models [19, 20]. Third, genetic 
analysis in Drosophila indicated that proliferating tissues 
from mutants carrying strong allelic combinations of the 
CIT-K orthologue were highly polyploid (8N or more), 
misshapen, and smaller than their wild type counterparts. 
By contrast, the tissues of animals carrying weaker allelic 
combinations were tetraploid and normal in shape and size 
[21]. These results indicate that, at least in Drosophila, 
low level of cytokinesis failure/polyploidy caused by 
hypomorphic CIT-K allelic combinations did not affect 
organ growth and structure, whereas multiple cytokinesis 
failures led to cell death and impaired tissue development. 
Therefore, it is conceivable that CIT-K inhibition could 
selectively affect the proliferation of very actively dividing 
cells. Finally, CIT-K could be potentially targeted by small 
molecule inhibitors designed to interfere with its ATP 
binding pocket, an approach successfully used to generate 
inhibitors of other cell division kinases of the Aurora and 
Polo-like kinase families that are currently in clinical trials 
for the treatment of various cancer pathologies [22].
We analyzed the effects of depleting CIT-K through 
RNA interference (RNAi) in a panel of cancer cell lines 
originating from breast, colorectal and cervical tissues. 
We found that, in all cell lines, CIT-K depletion caused 
cytokinesis failure, which decreased cell proliferation and 
triggered apoptosis via activation of executioner caspase 7. 
We also investigated why certain cancer cell lines elicited 
different sensitivities to CIT-K depletion and found that 
actively dividing cells and, to some extent, polyploid 
cells were significantly more sensitive to cytokinesis 
failure. These findings position CIT-K as a promising anti-
proliferative target for the potential treatment of a wide 
range of cancers characterized by active cell proliferation 
and polyploidy.
RESULTS
CIT-K is over-expressed and mutated in 
a variety of cancers, but does not possess 
oncogenic activity
We first sought to establish whether CIT-K had 
any oncogenic properties to eliminate the possibility of 
complications in our study linked to a potential ‘oncogene 
addiction’ effect. To this goal, we first analyzed the type 
and frequency of CIT mutations found in cancers from 
the catalogue of somatic mutations in cancer (COSMIC) 
database [23]. CIT was mutated in a low percentage (<5%) 
of cancers spread across a range of tissues (Supplementary 
Figure S1). Of these point mutations, the majority (65.16%) 
were missense mutations, just over a quarter (26.86%) were 
synonymous, and 6.12% were nonsense mutations (Figure 
1A). The remainder of mutations included either insertions 
or deletions, however these were at a very low frequency. 
Mapping the missense mutations on the CIT-K protein 
sequence revealed that there was an even distribution of 
mutations across the gene, with no single hotspot (Figure 
1B). However, there was an accumulation of mutations 
in the C-terminus of CIT-K between amino acids 1990 
and 2030. Interestingly, the C-terminal tail downstream 
of the CNH domain is subject to heavy phosphorylation, 
as indicated by our previous results [13] and by the data 
available at the PhosphoSitePlus database [24]. Although 
only one of these phosphosites was found mutated in the 
COSMIC database (S1948I, highlighted in bold in Figure 
1B), this evidence could nonetheless suggest that the 
C-terminal tail may have an important role in the regulation 
and/or function of CIT-K and could explain why it is often 
mutated in cancers.
We next wanted to develop a better understanding 
of how CIT mRNA expression varies in different cancers. 
To address this, we collected data from Oncomine™, 
a large database storing publically available cancer 
gene expression datasets [25]. In order to get the best 
representation of CIT mRNA expression in cancers, 
we collated data from all of the datasets available that 
compared cancer tissue versus the corresponding normal 
tissue and identified the datasets reporting significantly 
(p < 0.001) over- or under-expressed CIT mRNA. We 
set an arbitrary threshold value of 30%, above which we 
considered there was a meaningful amount of datasets 
showing significant CIT mRNA over- or under-expression 
for that specific cancer type. This meta-analysis revealed 
that CIT mRNA was significantly over-expressed in 
bladder, cervical, colorectal, esophageal, liver, lung, 
ovarian and sarcoma cancers (Figure 1C). Conversely, 
CIT mRNA was significantly under-expressed in bladder, 
brain/CNS, and leukemia cancers (Figure 1C).
To understand whether CIT over-expression could 
potentially translate into tumorigenic behaviour, we 
assessed whether CIT-K had any oncogenic properties. 
To this aim, we tested whether over-expression of CIT-K 
could promote proliferation in a colony formation assay in 
murine fibroblasts NIH3T3 cells. NIH3T3 cells lost contact 
inhibition and developed colonies when transfected with 
the constitutive active mutant form of human K-rasV12 
(hK-rasV12) (Figure 2A, 2B – condition 2). By contrast, 
over-expression of CIT-K in the absence of hK-rasV12 
did not increase colony formation compared to control 
conditions (Figure 2A, 2B – condition 3) and combined 
over-expression of CIT-K and hK-rasV12 significantly 
decreased colony formation (Figure 2A, 2B – condition 4). 
Over-expression of the mitotic kinase Aurora A – known 
to have oncogenic activity and thus used as control [26, 
27] – slightly increased colony formation (Figure 2A, 2B – 
condition 7) and a significant increase in colony formation 
was observed following over-expression of Aurora A::Venus 
with hK-rasV12 (Figure 2A, 2B – condition 8).
In conclusion, the combined analyses of CIT 
mutations and mRNA expression in cancers (Figure 1), 
and the effects of its over-expression data in NIH3T3 cells 
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Figure 1: Cancers display even distribution of somatic mutations across the CIT gene and predominately over-express 
CIT mRNA. A. CIT point mutations identified from the COSMIC database (gene ID: CIT_ENST00000261833) were categorized into 
types of mutations. The percentage each mutation type contributes is noted within each segment. B. CIT substitution missense mutations 
across the gene were calculated and mapped per 10 amino acids. A schematic representation of CIT-K is shown below the mutation 
histogram to visualise the location of the mutations. Phosphorylation sites identified from our laboratory and PhosphoSitePlus are listed 
below the CIT-K protein structure. S1948 is in bold and indicated by an asterisk to highlight that it was found mutated in the COSMIC 
database. CC, coiled coil; RBD, Rho/Rac binding domain; C1, cysteine-rich motif; PH, pleckstrin homology; CNH, Citron-NIK homology. 
C. CIT mRNA from cancerous tissue was datamined from the Oncomine™ database and compared against corresponding normal tissues 
to observe any over- or under-expression. All of the datasets on Oncomine™ were included in the analysis, whether they showed a 
significant (p < 0.001) difference in CIT mRNA expression or not. The bars show how many datasets showed either significant over- or 
under-expression, with the numbers above each bar indicating exactly how many of those datasets demonstrated a significant difference.
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(Figure 2), do not support the possibility of an oncogenic 
role for CIT-K.
CIT-K depletion causes cytokinesis failure 
in multiple cell lines and activates the Hippo 
tumor-suppressor pathway in normal, but not 
cancer cells
It has been reported that CIT-K knockout mice show 
polyploidy and cytokinesis failure only in the central 
nervous system and in testes [28, 29]. Thus, to understand 
the requirement of CIT-K for cytokinesis in human cells of 
different origins, we depleted CIT-K in various cancerous 
and non-cancerous immortalized cell lines, characterized 
by diverse karyotypes and p53 status (Table 1) [30-33].
We first analyzed the effect of CIT-K depletion by 
RNAi in HeLa Kyoto cervical cancer cells over a 96-hour 
time course (Figure 3A). Depleting CIT-K for 48 hours 
caused ~37% of cells to become multinucleated and 72 
and 96 hour treatments increased multinucleation to ~51% 
Figure 2: Over-expression of CIT-K does not increase colony formation. A. NIH3T3 cells were transfected with AcGFP empty 
vector, CIT-K::AcGFP, Venus empty vector and Aurora A::Venus in combination with either pBABE empty vector or pBABE-hK-rasV12. 
Cells were cultured for 2 weeks, fixed, stained with crystal violet and colonies counted. Images displayed show black and white contrast of 
crystal violet stain. The numbers on the top left of each condition denote the transfection treatment as shown in B. B. Quantification of the 
colonies counted from A. For each condition n=4, the experiment was completed in triplicate (pooled data, n=12). *p < 0.05, ***p < 0.001 
(Student’s t-test), n.s., not significant, error bars represent standard error of the mean (SEM).
Oncotarget87327www.impactjournals.com/oncotarget
and ~64%, respectively (Figure 3B). We then investigated 
whether CIT-K was essential for cytokinesis in a panel of 
cell lines comprising both non-cancerous immortalized 
cell lines (hTERT-RPE1 and HB4a) and cancer cell lines 
from breast (CAL51 and MDA-MB-231), colorectal 
(HCT116 and VACO5) and cervical (HeLa Kyoto and 
ME180) origins (Table 1). Western blot analysis confirmed 
an almost complete depletion of CIT-K in all cell lines 
after 48 hours, and persisting up to 96 hours, after siRNA 
treatment (Supplementary Figure S2). In all cell lines 
tested, CIT-K depletion caused significant cytokinesis 
failure after only 48 hours of treatment, with VACO5 
and ME180 cells experiencing the largest increases 
of multinucleation (Figure 3C, Supplementary Figure 
S3). We also confirmed that CIT-K siRNA depletion 
activated the Hippo tumor suppressor pathway through 
phosphorylation of LATS2 in hTERT-RPE1 cells (Figure 
3D, left panel), as previously demonstrated in other 
cases of cytokinesis failure [34]. However, the Hippo 
tumour suppressor pathway after CIT-K depletion was 
not activated in HeLa Kyoto or HCT116 cancer cell lines 
(Figure 3D, middle and right panels), suggesting that at 
least some cancer cells have adapted to inhibit or bypass 
this control mechanism.
In conclusion, our results indicate that CIT-K 
depletion triggers cytokinesis failure in many cell types, 
independently of their origin and other characteristics such 
as ploidy and p53 status.
Table 1: Detailed characterisation of cell lines analyzed
Cell line p53 Ploidy CIN
Multi-
nucleation 
fold diff.
Proliferation 
fold diff.
Apoptotic 
fold diff.
Doubling 
time 
(hours)
CIT-K 
expression
TUBB3 
expression
hTERT-
RPE1
WT 46 - 5.14 1.543 2.166 29 0.711 29.51
HB4a WT 69 n/a 9.90 1.967 1.683 27.7 0.299 6.711
CAL51 WT 46 n/a 8.85 1.481 1.305 28.2 0.647 0.736
MDA-
MB-231 R280K 64 n/a 3.40 1.481 1.575 31.8 1.943 0.471
HeLa Kyoto HPV+ve 67 + 7.10 2.248 2.271 25.9 0.862 0.769
ME180 HPV+ve 63 n/a 17.79 2.243 1.855 22.2 1.624 0.075
HCT116 WT 45 - 3.56 1.196 1.162 24.7 0.121 1.488
LoVo WT 49 - n/a 1.842 n/a n/a 0.454 0.233
LS147T WT 45 - n/a 2.197 n/a n/a 0.028 0.047
VACO5 R282W 46 - 21.83 2.102 2.193 17.7 0.111 0.104
Caco2 E204X 96 + n/a 1.374 n/a n/a 0.557 1.258
HT29 R273H 71 + n/a 1.435 n/a n/a 0.705 0.391
SW620 R273H 50 + n/a 1.226 n/a n/a 0.485 1.545
SW403 E51X 68 + n/a 1.676 n/a n/a 7.697 2.243
HCT116 
p53+/+ WT n/a - 8.77 1.443 n/a 32.9 n/a n/a
HCT116 
p53-/- Null n/a n/a 2.65 1.561 n/a 25.9 n/a n/a
HCT116 2N WT 2N (46) - n/a 1.570 n/a n/a n/a n/a
HCT116 4N WT 4N (92) n/a n/a 1.725 n/a n/a n/a n/a
Nine parameters were assessed: p53 status; ploidy; CIN; multinucleation, proliferation and apoptosis fold difference 
(fold diff.) following CIT-K depletion; doubling time; CIT-K and TUBB3 protein expression levels. The ploidy of each 
cell line was obtained from the American Type Culture Collection or the references stated in the text. CIT-K and TUBB3 
expressions were normalized to tubulin. WT, wild type; n/a, not available.
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CIT-K RNAi inhibits cell proliferation and 
induces cell death through apoptosis
As our findings indicated that multinucleation 
increased following CIT-K depletion, we investigated how 
cytokinesis failure affected cell proliferation. We found 
that cell proliferation decreased in all cell lines after CIT-K 
RNAi when compared against control cells treated with a 
scrambled siRNA (Figure 4A, Supplementary Figure S2). 
We calculated the fold difference in proliferation after 96 
hours of CIT-K siRNA treatment (Figure 4B, Table 1), 
which revealed that the colorectal cell line VACO5 and 
the cervical cell lines HeLa Kyoto and ME180 were most 
affected (fold difference greater than 2). We also found a 
positive correlation (R2 = 0.483) between the increase in 
multinucleation and the decrease in proliferation in CIT-K 
depleted cells (Figure 4C).
To understand the effects of long term CIT-K 
depletion, we performed several rounds of siRNA 
transfection and measured cell number at various time 
points over two weeks (Figure 4D, Supplementary Figure 
S4). Long-term depletion of CIT-K caused a continuous 
decrease in cell proliferation, as observed by an increased 
doubling time (Td) of CIT-K depleted cells, and after day 
12 almost no proliferation occurred (Figure 4D, 4E). 
Measuring the fold difference between CIT-K depleted 
cells and control siRNA-treated cells revealed that, over 
time, the difference in proliferation increased dramatically, 
which correlates with increased multinucleation over time 
(Figure 4E, 3B).
We then investigated the fate of CIT-K-
depleted multinucleated cells. We measured cell death 
using an annexin V apoptotic assay combined with 
Figure 3: CIT-K is essential for the completion of cytokinesis in a panel of cancer cell lines. A. HeLa Kyoto cells were 
plated on coverslips and treated with a siRNA against either a random sequence (control) or CIT-K for 48, 72 and 96 hours (h), where 
cells were fixed and stained to detect tubulin (green) and DNA (blue). Bars, 10 μm. B. Quantification of multinucleation increase from the 
experiment shown in A. At least 600 cells were counted for analysis in each experiment, n=3, error bars represent SEM. C. Quantification 
of the percentage of multinucleated cells (of cell lines listed) that were treated with either control or CIT-K siRNA for 48 h. Cells were fixed 
and stained to detect tubulin (green), phalloidin (red) or DNA (blue). The fold difference between control and CIT-K siRNA-treated cells is 
listed above each cell line. At least 600 cells were counted for analysis in each experiment, n=3, error bars represent SEM. D. hTERT-RPE1 
(left panel), HeLa Kyoto (middle panel) and HCT116 (right panel) cells were treated with either control or CIT-K siRNA for 48 h, harvested 
and protein extracts analyzed by Western blot to detect CIT-K, phosphorylated LATS (pLATS), LATS2 and tubulin. The numbers on the left 
indicate the sizes in kilodaltons of the molecular mass marker.
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Figure 4: Depleting CIT-K decreases cell proliferation in cancer cells. A. Cell lines were plated the day prior to transfection and 
were either untreated or treated with control or CIT-K siRNA at day 0 for up to 96 hours. Cell number was calculated at each time point and 
an aliquot of cells taken for Western blot analysis. Each condition was performed in triplicate, error bars represent SEM. B. Quantification 
of fold difference between control and CIT-K-siRNA treated cells at 96 h, n=3 (pooled data from A, n=9), error bars represent SEM. The 
dotted line represents a fold difference of 1 (being no difference in proliferation compared to control). Values above this line indicate a 
decrease in proliferation. C. Correlation analysis of multinucleation and proliferation fold differences. The values used for analysis can be 
found in Table 1. The Pearson correlation coefficient (R2) is listed next to the linear trend line. D. HeLa Kyoto cells were treated with either 
control or CIT-K siRNA for up to 96 h, where cells were counted, re-plated and transfected the subsequent day, for up to 14 days. At each 
time point an aliquot of cells was taken for Western blot analysis. The doubling time of cells (Td) was calculated over a 96 hour time period 
(day 0 to 4, day 5 to 9 and day 10 to 14) and listed next to the cell proliferation curve. Each condition was performed in triplicate, error 
bars represent SEM. E. Quantification of the experiment shown in D showing the proliferation fold difference between control and CIT-K 
siRNA-treated cells at each time point.
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propidium iodide (PI) staining. Annexin V binds to 
phosphatidylserines that have flipped to the extracellular 
surface, identifying early apoptotic events in apoptosis, 
whereas combined PI staining marks late apoptotic 
events. Depleting CIT-K induced an apoptotic response, as 
indicated by an increase in both early apoptotic (annexin 
V positive, PI negative) and late apoptotic (annexin V 
positive, PI positive) cell populations (Figure 5A-5H). It 
is noteworthy that cell lines that either carry p53 mutations 
(MDA-MB-231 and VACO5) or have inactive p53 due to 
HPV infection (HeLa Kyoto and ME180) were still able 
to initiate apoptosis following CIT-K depletion (Figure 
5D, 5F-5H), indicating that CIT-K depletion triggers cell 
death via p53-dependent and independent pathways. There 
was an increase in fold difference of both early and late 
apoptotic cell populations across all the cell lines tested 
(Figure 5I, Table 1), and we found a positive correlation 
(R2 = 0.516) between the level of proliferation decrease 
and the level of apoptosis (Figure 5J, Table 1) and a weak 
positive correlation (R2 = 0.166) between the increase of 
multinucleation and apoptosis after depletion of CIT-K 
(Figure 5J, Table 1).
To confirm that the proliferation and apoptotic 
defects could be rescued by a siRNA-resistant CIT-K 
transgene, we generated monoclonal HeLa Kyoto cell lines 
stably expressing either human CIT-K tagged with AcGFP 
(Aequorea coerulescens GFP) or AcGFP alone. CIT-
K::AcGFP correctly localized to the midbody ring like its 
endogenous counterpart (Supplementary Figure S5) [13] 
and was able to rescue cytokinesis failure, proliferation 
decrease and induction of apoptosis after depletion of 
endogenous CIT-K using an siRNA directed against the 
CIT-K 3’UTR, which is not present in the CIT-K::AcGFP 
transgene (Figure 6A-6D, Supplementary Figure S6). 
These results demonstrate that all these phenotypes 
are specific to CIT-K loss rather than off-target effects. 
Notably, cells over-expressing CIT-K::AcGFP proliferated 
much slower than control cells (Figure 6C), which is 
consistent with the published observation that cells over-
expressing CIT-K take longer to complete abscission [15], 
and provides further evidence that CIT-K does not behave 
as an oncoprotein.
To conclude, our results indicate that cytokinesis 
failure caused by CIT-K depletion drastically inhibits cell 
proliferation and induces apoptosis in a variety of cancer 
cell lines.
Both p53-dependent and independent pathways 
initiate apoptosis after cytokinesis failure
It is well known that p53 is one of the main 
factors that can induce apoptosis in response to 
various stress signals [35]. However, we observed an 
increase in apoptosis after CIT-K depletion in cancer 
cells with impaired p53 functions (Figure 5D, 5F-5H). 
To investigate the role of p53 in cell death induced 
by cytokinesis failure, we used two isogenic strains 
of the colon carcinoma cell line HCT116: a parental 
p53+/+ cell line and a mutated p53-/- cell line [36]. We 
first analyzed the DNA content of both lines and found 
an increased amount of cells containing 4N in the 
p53-/- cell population when compared to p53+/+ cells 
(Figure 7A). This was recapitulated by transiently 
knocking down p53 in HCT116 p53+/+ cells (Figure 
7B). Interestingly, a greater level of multinucleation 
was observed in p53-/- cells (7.97%) compared to p53+/+ 
cells (2.21%) under control conditions (Supplementary 
Figure S7A, S7B), indicating, as expected, that p53 
is necessary to prevent multinucleation. We found 
that loss of p53 affected cell proliferation after CIT-K 
depletion, as HCT116 p53-/- cells showed a slight, but 
significant, reduction in their proliferation compared 
to p53+/+ cells (Figure 7C, 7D, Supplementary Figure 
S7A, S7B). Interestingly, although p53-/- cells divided 
more slowly after CIT-K depletion, they did not appear 
to initiate apoptosis (Figure 7E, 7F). CIT-K depletion 
in HCT116 p53+/+ cells caused an increase in cleaved 
executioner caspase 7 (cC7) and its downstream 
target poly(ADP-ribose) polymerase (cPARP), but not 
executioner caspases 3 (cC3) and 6 (cC6) (Figure 7G, 
7H), indicating that, in these cells, cytokinesis failure 
triggers apoptosis primarily via caspase 7 activation. By 
contrast, depleting CIT-K in p53-/- cells did not increase 
cleavage of PARP or any major executioner caspases 
(Figure 7G, 7H), consistent with the well-known pro-
apoptotic role of p53.
Interestingly, the HCT116 p53-/- cells exhibited an 
increase of CIT-K expression (Figure 7G). To determine 
whether this is a real effect due to loss of p53 or an artifact, 
we transiently depleted p53 over a time course of 96 
hours and found that CIT-K was significantly upregulated 
compared to control conditions (Supplementary Figure 
S8A, S8B). Together, this suggests that p53 could 
somehow regulate the expression of CIT-K, potentially 
functioning in an inhibitory manner.
The finding that p53 is required for apoptosis 
following cytokinesis failure in HCT116 cells is in 
contrast with our observation that other p53-defective 
cancer cell lines were able to initiate apoptosis after 
depletion of CIT-K (Figure 5D, 5F-5H). To eliminate the 
possibility that these cell lines could still possess some 
residual p53 apoptotic functions, we measured apoptosis 
after co-depletion of CIT-K and p53 in p53-mutated 
VACO5 colorectal cancer cells. No significant difference 
in apoptosis was observed between VACO5 cells treated 
either with CIT-K siRNA alone or with both CIT-K and 
p53 siRNAs (Figure 8A-8C), indicating that p53-mutated 
cells undergo cell death via a p53-independent apoptotic 
mechanism after depletion of CIT-K. In conclusion, 
these results demonstrate that cytokinesis failure triggers 
apoptosis via both p53-dependent and independent 
pathways.
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Figure 5: Cytokinesis failure induces apoptosis in cancer cells. A-H. Cell lines were plated the day prior to transfection and were 
either untreated or treated with control or CIT-K siRNA for 72 h. Cells were harvested and stained with annexin V and propidium iodide (PI) 
to detect early apoptosis (annexin V positive, PI negative) and late apoptosis (annexin V positive, PI positive). Quantification of the flow 
cytometric data on the left is shown to the right, n=3. 20,000 cells were used in each analysis, error bars represent SEM. I. Quantification 
of fold difference between control and CIT-K-siRNA treated cells, n=3 (pooled data from A-H, n=9), error bars represent SEM. The dotted 
line represents a fold difference of 1; values above this line indicate an increase in apoptosis. J. Correlation analysis of proliferation and 
apoptotic fold differences. The values used for apoptotic fold difference is from the combined ‘Early + Late’ population. K. Correlation 
analysis of multinucleation and apoptotic fold differences. The Pearson correlation coefficients (R2) are listed next to the linear trend lines. 
The values used in J and K can be found in Table 1.
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Figure 6: Exogenously expressed CIT-K rescues endogenously depleted CIT-K defects. A. HeLa Kyoto cells stably 
expressing AcGFP or CIT-K::AcGFP were treated with either control or 3’UTR CIT-K siRNA for 48 h, and then cells were harvested 
and protein extracts analyzed by Western blot to detect CIT-K and tubulin. B. AcGFP and CIT-K::AcGFP cell lines were plated on glass 
coverslips and treated with either control or 3’UTR CIT-K siRNA for 48 h, and then cells were fixed and stained to detect tubulin and 
DNA by immunofluorescence microscopy. Over 600 cells were counted per condition, n=3, error bars represent SEM. C. AcGFP and CIT-
K::AcGFP cell lines were treated with either control or 3’UTR CIT-K siRNA over a time course of 96 h, where at the respective time point 
the cell number was determined. Error bars represent SEM, n=3. D. AcGFP and CIT-K::AcGFP cell lines were treated with either control 
or 3’UTR CIT-K siRNA for 72 h, and then cells were harvested and stained with annexin V and PI to detect early and late apoptosis. Bar 
graph shows quantification of the flow cytometric data, n=4, 10,000 cells were used in each analysis, error bars represent SEM.
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Figure 7: p53-dependent and independent pathways exist to initiate apoptosis following CIT-K depletion. A. HCT116 
p53+/+ and p53-/- cells were fixed in 70% ethanol and treated with PI/RNase solution to detect DNA content. 4N DNA content was analyzed 
by gating for the second, G2/M peak. 20,000 cells were used for each analysis, n=7, ***p < 0.001 (Student’s t-test), error bars represent 
SEM. B. HCT116 p53+/+ cells were treated with either control or TP53 siRNA for 48 h, harvested, fixed in 70% ethanol and treated with PI/
RNase solution to detect DNA content. 4N DNA content was analyzed by gating for the second, G2/M peak. 20,000 cells were used for each 
analysis, n=6, ***p < 0.001 (Student’s t-test), error bars represent SEM. C. HCT116 p53+/+ and p53-/- cells were plated prior to transfection 
and were either untreated or treated with control or CIT-K siRNA at day 0 for up to 96 h. Cell number was calculated at each time point, 
each condition was performed in triplicate, error bars represent SEM. D. Quantification of fold difference between control and CIT-K-
siRNA treated cells at 96 h, n=6 (pooled data from C, n=18), *p < 0.05 (Student’s t-test), error bars represent SEM. E. HCT116 p53+/+ and 
p53-/- cells were treated with either control or CIT-K siRNA for 72 h, where cells were harvested and stained with annexin V and PI to detect 
apoptosis. 20,000 cells were used in each analysis. F. Quantification of the flow cytometric data shown in E. Errors bars represent SEM, 
n=3. G. HCT116 p53+/+ and p53-/- cells were treated with either control or CIT-K siRNA for 48 h, harvested and protein extracts analyzed 
by Western blot to detect CIT-K, cleaved PARP, cleaved caspases 3, 6 and 7, p53 and tubulin. The numbers on the left indicate the sizes 
in kilodaltons of the molecular mass marker. H. Band intensities of the Western blot analysis from G was analyzed by ImageJ, normalized 
to tubulin, and the fold difference between CIT-K and control siRNA lysates calculated. The dotted line represents a fold difference of 1; 
values above this line indicate an increase of protein cleavage and thus activation.
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Tetraploid and actively dividing cells are more 
sensitive to cytokinesis failure
Comparative analysis of cell proliferation after 
CIT-K depletion in eight different cell lines (Figure 4A, 
4B) indicated that the cells that had the largest decreases in 
proliferation were VACO5, HeLa Kyoto and ME180, all of 
which have impaired p53 functions (Table 1). Therefore, 
we reasoned that inactivation of p53 could potentially 
render cells more susceptible to cytokinesis failure, 
which was also consistent with our finding that HCT116 
p53-/- cells proliferated slower than their parental p53+/+ 
cells after CIT-K depletion (Figure 7C, 7D). To address 
this, we extended our panel of colorectal cell lines to 
include additional lines harboring either wild type (LoVo 
and LS147T) [33] or mutated p53 genes (Caco2, HT29, 
SW620 and SW403) [33, 37, 38] (Table 1). Western blot 
analysis confirmed a severe knockdown of CIT-K in all six 
additional cell lines (Supplementary Figure S9). However, 
contrary to our expectation, the p53 status did not appear 
to be a major determining factor in the susceptibility of 
cancer cells to cytokinesis failure (Figure 9A, Table 1). 
Similarly, CIN status also did not seem to be a contributing 
factor (Figure 9B, Table 1).
We then investigated whether CIT-K expression 
levels could determine how cells responded to CIT-K 
knockdown, but found no significant correlation (R2 
= 0.001) between the level of CIT-K expression and 
proliferation decrease (Figure 9C, 9D, Table 1), consistent 
with the finding that over-expression of CIT-K does 
not possess oncogenic potential (Figure 2A and 2B). It 
was recently reported that tubulin β-III (TUBB3) over-
expression increased sensitivity to CIT-K depletion in 
HeLa cells [39]. However, our analysis indicated no 
correlation (R2 = 0.019) between the level of TUBB3 
expression and how cells responded to CIT-K knockdown 
(Figure 9C, 9E, Table 1).
Our findings indicated that high levels of 
multinucleation induced by long CIT-K RNAi treatments 
resulted in large decreases in cell proliferation (Figures 
3B, 4D), suggesting that an increase in ploidy might 
render cells more sensitive to cytokinesis failure. To 
address this hypothesis, we generated a tetraploid 
HCT116 cell line by inducing a single round of 
cytokinesis failure using the actin depolymerizing 
drug cytochalasin D (Figure 9F) and compared how 
these cells responded to CIT-K depletion with respect 
to their parental diploid counterparts. Western blot 
Figure 8: VACO5 colorectal cells still undergo apoptosis when co-depleted for CIT-K and p53. A. VACO5 cells were 
treated with control, CIT-K or combination CIT-K/TP53 siRNA for 72 h, where cells were harvested and stained with annexin V and PI to 
detect apoptosis. 50,000 cells were used in each analysis. B. Quantification of the early apoptotic fraction (annexin V positive, PI negative). 
Error bars represent SEM, n=4, *p < 0.05 (Student’s t-test), n.s., not significant. C. VACO5 cells were treated with control, CIT-K or 
combination CIT-K/TP53 siRNA for 72 h, where cells were harvested and protein extracts analyzed by Western blot to detect CIT-K, p53 
and tubulin. The numbers on the left indicate the sizes in kilodaltons of the molecular mass marker.
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Figure 9: Tetraploid cells are more sensitive to the depletion of CIT-K compared to their diploid counterparts. A. 
Cell lines listed were treated with control or CIT-K siRNA for 96 h, cell number calculated and the fold difference between control and 
CIT-K siRNA-treated cells quantified. For each condition n=3, with the experiment performed in triplicate (pooled data, n=9), error bars 
represent SEM. The cell lines are sorted into having normal or impaired p53 functions. B. Cells listed were treated as described in A, but 
were characterized depending on whether they possessed CIN (+) or not (-). C. Protein extracts of all the cell lines tested were analyzed by 
Western blot to detect CIT-K, TUBB3 and tubulin. The numbers on the left indicate the sizes in kilodaltons of the molecular mass marker. 
D. Correlation analysis of proliferation fold difference and CIT-K expression (from C, CIT-K normalized to tubulin) of each cell line. The 
Pearson correlation coefficient (R2) is listed next to the linear trend line. E. Correlation analysis of proliferation fold difference and TUBB3 
expression (from C, CIT-K normalized to tubulin) of each cell line. F. HCT116 2N and 4N cells were fixed in 70% ethanol and treated with 
PI/RNase solution to detect DNA content. 50,000 cells were used for each analysis. G. HCT116 2N and 4N cells were treated with either 
control or CIT-K siRNA for 48 h, harvested and protein extracts analyzed by Western blot to detect CIT-K and tubulin. The numbers on the 
left indicate the sizes in kilodaltons of the molecular mass marker. H. HCT116 2N and 4N cells were treated with either control or CIT-K 
siRNA for 48 h, counted and the fold difference between control and CIT-K siRNA-treated cells quantified. For each condition n=9, *p < 
0.05 (Student’s t-test), error bars represent SEM. I. Correlation analysis of proliferation fold difference and chromosome number of each 
cell line. J. Correlation analysis of proliferation fold difference and doubling time of cell lines. The values used for D, E, I and J can be 
found in Table 1.
Oncotarget87336www.impactjournals.com/oncotarget
analysis indicated that there was no difference in the 
level of CIT-K expression and CIT-K RNAi knockdown 
efficiency between the two cell lines (Figure 9G). We 
found that tetraploid HCT116 cells were more sensitive 
to cytokinesis failure than diploid cells, as shown by a 
significant difference in cell proliferation (Figure 9H, 
Table 1). However, when we plotted the proliferation 
fold difference against the chromosome numbers of all 
the cell lines used in this study, no direct correlation 
(R2 = 0.004) was observed (Figure 9I). We did, instead, 
find a modest positive correlation (R2 = 0.313) between 
the cell cycle rate and the decrease in cell proliferation 
(Figure 9J), suggesting that fast dividing cells are more 
susceptible to cytokinesis failure.
Taken together, all these results indicate that 
CIT-K depletion was particularly effective in blocking 
the proliferation of polyploid and actively dividing cells, 
irrespective of the level of CIT-K expression, p53 status 
and CIN.
DISCUSSION
The discovery and validation of new targets for the 
treatment of cancers is essential for improving patient 
survival. Here we investigated the potential of inducing 
cytokinesis failure via depletion of CIT-K as an anti-
proliferative anti-cancer approach in breast, cervical 
and colorectal cancers. Our results indicate that CIT-K 
is essential for cytokinesis in all cancer cell lines, which 
contrasts with the evidence that in CIT-K null mice 
cytokinesis failure was only observed in brains and testes 
[28, 29]. It is therefore likely that CIT-K is necessary for 
cytokinesis across a wider range of human tissues than 
initially anticipated from studies in mice. These findings 
also suggest that, notwithstanding the high level of 
sequence conservation between mice and human genes, 
their functions and requirement can differ in the two 
organisms and caution should be taken in assuming that 
knowledge gained from studies in mice could be directly 
transferred to human systems.
The Hippo tumor suppressor pathway was activated 
after CIT-K depletion through phosphorylation of LATS2 
in non-cancerous immortalized hTERT-RPE1 cells (Figure 
3D, left panel), which acts to limit cell proliferation by 
negatively regulating growth transcriptional co-activators 
YAP and TAZ and by stabilizing p53 [34]. The Hippo 
pathway is well known to regulate apoptosis to control 
organ size and to respond to DNA damage [40-43], 
but whether it can regulate apoptosis in response to 
tetraploidization is not clear. The Hippo tumor suppressor 
pathway has been shown to be deregulated in a broad 
range of cancers, contributing towards tumorigenesis 
[44]. In support of this, we show that HeLa Kyoto and 
HCT116 cancer cells did not activate the Hippo pathway 
after cytokinesis failure (Figure 3D, middle and right 
panels), suggesting that these cancer cells have evolved 
alternative pathways to detect cytokinesis failure (see also 
next paragraphs).
CIT-K depletion induced apoptosis through 
executioner caspase 7 and PARP (Figure 7G, 7H). 
Interestingly, executioner caspases 3 and 6 were not 
activated, which is not surprising as this caspase network 
is known to possess distinct, non-redundant functions [45-
47]. Loss of p53 also causes polyploidy (Figure 7A, 7B) 
[48-50], which in turn can render cells more susceptible to 
CIT-K depletion (Figure 7C, 7D). In addition, our results 
suggest that cytokinesis failure can trigger apoptosis via 
distinct mechanisms in cancer cells (Figures 5, 7, 8). 
We found that p53 was essential for initiating apoptosis 
following cytokinesis failure in HCT116 cells (Figure 
7E-7H), as previously reported [51, 52]. However, 
cells with impaired p53 functions (i.e. MDA-MB-231, 
VACO5, HeLa Kyoto and ME180) were still able to 
initiate apoptosis (Figure 5A-5I), even after p53 RNAi 
(Figure 8A-8C), suggesting that these cells have acquired 
p53-independent mechanisms to trigger apoptosis. It is 
unclear why there is this apoptotic discrepancy between 
the isogenic HCT116 strains and the p53-defective lines, 
but one possibility is that it could be a difference in how 
cells have evolved in the complete absence versus just 
mutation of p53.
What could be the apoptosis-trigger mechanism 
in p53-deficient cells? The cyclin-dependent kinase 
inhibitor p21 is activated by p53 to inhibit S phase entry 
to allow the cell time to repair any potential DNA damage. 
However, p21 can be activated independently of p53 to 
promote apoptosis [53], and it is therefore conceivable that 
p21 could be responsible for regulating/initiating apoptosis 
in response to CIT-K depletion in cells harboring p53 
mutations. Indeed, Chk2 has been shown to activate p21 
independently of p53 leading to cell cycle arrest, apoptosis 
and senescence [54]. Importantly, these results, along 
with the lack of correlation between the p53 status and 
susceptibility to CIT-K depletion (Figure 9A), indicate that 
cytokinesis failure could be an effective anti-proliferative 
approach for treating cancers carrying either wild type 
or mutated p53. This evidence, along with our findings 
that CIT-K depletion inhibited proliferation in all cancer 
cell lines and the studies mentioned earlier in prostate and 
hepatocellular cancer cells [19, 20], suggest that targeting 
CIT-K might be a potentially valid therapeutic approach 
for the treatment of various cancer types. However, 
our study also indicates that CIT-K depletion was more 
effective in actively dividing and, in some cases, polyploid 
cancer cells (Figure 9A, 9H and 9J), which suggests that 
inhibiting cytokinesis might be an effective strategy for 
the treatment of fast proliferating, Myc-driven cancers. 
Additional in vivo studies, however, are necessary to test 
these hypotheses.
CIT-K’s kinase activity is required for completion 
of cytokinesis [12, 13, 55] and this kinase has been shown 
to phosphorylate itself and the INCENP component of 
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the chromosomal passenger complex [13]. Together, 
these findings would indicate that the isolation of small 
molecules able to interfere with the ATP binding pocket 
of CIT-K could be a feasible objective and these inhibitors 
might become valid anti-proliferative tools in cancer 
therapy. In addition, as mentioned earlier, CIT-K is an 
attractive target because it is the only kinase to function 
solely in cytokinesis – in contrast to other kinases such 
as Aurora B and Plk1, which possess pleiotropic roles 
throughout mitosis – and thus it is conceivable that 
targeting CIT-K could cause less undesired side effects.
Finally, it is important to consider that targeting 
cytokinesis as a means of cancer therapy is a double-
edged sword approach. On the one hand, it is effective 
in inducing cell death, on the other, cytokinesis 
failure and polyploidy have been shown to promote 
tumorigenesis, CIN and drug resistance [7-9, 56, 57]. 
However, tumorigenesis is only promoted in tetraploid 
cells devoid of p53, implying that, if healthy cells were 
subject to cytokinesis failure, p53 would limit CIN [7]. 
Therefore, although it seems likely that long treatments 
with cytokinesis inhibitors may quash potential cancer-
generating tetraploid cells, caution has to be taken when 
investigating the use of cytokinesis inhibitors in cancer 
therapy.
MATERIALS AND METHODS
Cell lines
All cells were maintained at 37°C, 5% CO2. 
hTERT-RPE1, CAL51, MDA-MB-231, HCT116 (all 
variants), VACO5, HT29, LoVo, LS147T, SW620, Caco2 
and SW403 cells were cultured in DMEM/F12, 2mM 
L-glutamine and 10% FBS. HeLa Kyoto cells (wild type, 
AcGFP and CIT-K::AcGFP stable cell lines) were cultured 
in DMEM GlutaMAX and 10% FBS. HB4a cells were 
cultured in RPMI-1640, 5 μg/ml hydrocortisone, 5 μg/
ml insulin and 10% FBS. ME180 cells were cultured in 
GMEM, 2mM L-glutamine and 10% FBS. NIH3T3 cells 
were cultured in DMEM and 10% NCS. Generation of 
the AcGFP and CIT-K::AcGFP cell line was performed 
as previously described [13], however we used the 
pIRESpuro3 vector (Clontech) with Flag and AcGFP 
C-terminal tags (for simplicity this construct was referred 
to as AcGFP).
Antibodies
The following antibodies were used: mouse 
monoclonal anti-α-tubulin (clone DM1A, Sigma, T9026), 
mouse monoclonal anti-CIT-K (BD Transduction 
Laboratories, 611377), rabbit anti-cleaved caspase 3 (Cell 
Signaling Technology, CST, 9661), rabbit anti-cleaved 
caspase 6 (CST, 9761), rabbit anti-cleaved caspase 7 
(CST, 9491), rabbit anti-cleaved PARP (CST, 9541), 
mouse monoclonal anti-p53 (clone D0-1, Santa Cruz 
Biotechnology, sc-126), rabbit anti-phosphorylated LATS 
(CST, D57D3), rabbit anti-LATS2 (Bethyl Laboratories, 
A300-479A) and mouse monoclonal anti-TUBB3 (clone 
2G10, Abcam, ab78078). Peroxidase and Alexa-fluor 
conjugated secondary antibodies were purchased from 
Jackson Laboratories and Invitrogen respectively.
Colony formation assay
NIH3T3 cells were plated at a density of 1x105 per 
6cm dish and were transfected with 1 μg of respective 
DNA using FuGENE HD Transfection Reagent (Promega) 
according to manufacturer’s instructions, at a FuGENE 
HD:DNA ratio of 3:1 for total DNA transfected. Media 
was changed every 4 days for 2 weeks, where cells 
were then fixed in PHEM buffer (60 mM PIPES, 25 
mM HEPES pH 7, 10 mM EGTA, 4 mM MgCl2, 3.7% 
[v/v] formaldehyde) for 15 minutes and stained with 
crystal violet solution (0.5% [w/v] crystal violet and 
25 mM HEPES) for 60 minutes. Crystal violet solution 
was washed off with Milli-Q water. Colonies above 
2 mm in diameter were counted for analysis. The 
following plasmids were used: pBABE empty vector, 
pBABE::hK-rasV12, pIRESpuro3::AcGFP empty vector, 
pIRESpuro3::CIT-K::AcGFP, Venus empty vector and 
Aurora A::Venus (kind gifts of Dr. C. Lindon, University 
of Cambridge).
siRNA transfection
The following siRNAs were 
used: scrambled sequence control – 
5’-AACGUACGCGGAAUACUUCGA-3’, CIT-K – 
5’-AUGGAAGGCACUAUUUCUCAA-3’, 3’UTR CIT-K 
– 5’-CACACUAUGGAACUCUGCU-3’, TP53 – a pool 
of siRNAs were purchased from Dharmacon. All siRNAs 
were transfected at a concentration of 12 nM using 
lipofectamine RNAiMAX (Thermo Fisher Scientific) 
following the manufacturer’s instructions, where cells 
were then washed with PBS and maintained under normal 
culture conditions for the specified time.
Immunofluorescence multinucleation assay
Cells were grown on microscope glass coverslips 
(Menzel-Gläser), treated with respective siRNAs for the 
specified time and fixed in PHEM buffer for 12 min. 
They were then washed three times for 10 min with 
PBS and incubated in blocking buffer (PBS, 0.5% [v/v] 
Triton X-100 and 1% [w/v] BSA) for 1 hour (h) at room 
temperature (RT). Coverslips were incubated overnight 
at 4°C with the primary antibodies indicated in the figure 
legends, diluted in PBT (PBS, 0.1% [v/v] Triton X-100 
and 1% [w/v] BSA). The following day, coverslips were 
washed twice for 5 min in PBT, incubated with secondary 
antibodies diluted in PBT for 2 h at RT and then washed 
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twice with PBT and once with PBS. Coverslips were 
mounted on SuperFrost Microscope Slides (VWR) using 
VECTASHIELD Mounting Medium containing DAPI 
(Vector Laboratories). Over 600 cells per condition were 
counted for analysis.
Proliferation assay
Cell proliferation was measured by counting 
absolute cell number. Cells were treated with respective 
siRNAs for the specified time, harvested by trypsinisation, 
an aliquot of cells was stained with an equal volume of 
0.4% [w/v] trypan blue (Sigma Aldrich), pipetted into 
disposable Countess® chamber slides and counted using 
the Countess® Automated Cell Counter (Thermo Fisher 
Scientific). Only viable cells were measured in the 
analysis. Doubling time (Td) of cells was calculated with 
the following formula: Td = duration of analysis (hours) / 
(log(final cell number / initial cell number) / log(2)).
Apoptosis assay
Cells were treated with respective siRNAs for 72 
hours, harvested using non-enzyme dissociation buffer 
(Sigma Aldrich) and kept on ice. The media and PBS 
wash prior to harvesting were collected as apoptotic 
cells can become buoyant. Dissociated cells were 
carefully collected, washed twice in ice cold PBS and 
once in 1X annexin V binding buffer (BD Pharmingen). 
Approximately 1x105 cells were stained with annexin 
V-FITC (BD Pharmingen) for 15 minutes in the dark at RT 
and then with PI (BD Pharmingen) just prior to analysis on 
the Cytek FACScan™ Flow Cytometer. 20,000 cells were 
used in the analysis.
Cell cycle analysis
Cells were harvested, washed with PBS and fixed 
for 30 minutes at 4ºC with ice cold 70% [v/v] ethanol 
(adding ethanol drop wise to cells whilst vortexing). 
Fixed cells were washed with PBS and re-suspended in 
FxCycle™ PI/RNase Staining Solution (Life technologies) 
for 15 minutes prior to analysis on the Cytek FACScan™ 
Flow Cytometer. 50,000 cells were used in the analysis, 
unless stated otherwise.
Generation of tetraploid HCT116 cell line
HCT116 cells (the HCT116 p53+/+ strain was 
used) were treated with 4 μM cytochalasin D (Sigma 
Aldrich) for ~18 hours, washed every 5 minutes for 30 
minutes with PBS, stained with 15 μM Hoescht 33342 
for 30 minutes at 37°C and then FACS sorted for the 
8N population (to isolate dividing 4N cells). Cells were 
grown until near confluent in a T75 flask where they 
were again sorted for the 8N population (no treatment 
with cytochalasin D on subsequent sorts). This process 
was repeated twice more until a near pure population 
of dividing HCT116 4N cells were achieved. For 
the parental 2N cell line, cells were sorted for the 2N 
population following cytochalasin D treatment and 
cultured under normal conditions.
Oncomine™ analysis
The following datasets were used to analyse CIT 
mRNA expression in cancers compared to healthy tissue. 
Where the dataset ID was not available (typically prefaced 
by GSE), the PubMed ID (PMID) was given. Bladder: 
GSE13507, GSE3167, GSE89, PMID 16432078. Brain: 
GSE2223, GSE4290, GSE4058, GSE4536, GSE7696, 
TCGA, PMID 12894235, PMID 11929829, PMID 
16357140. Breast: GSE3744, GSE3193, GSE4382, 
GSE5764, GSE22358, GSE1477, GSE3971, GSE14548, 
GSE8977, GSE9014, TCGA, PMID 10963602, PMID 
22522925. Cervical: GSE7410, GSE6791, GSE9750, 
GSE7803. Colorectal: GSE20916, GSE9689, GSE20842, 
GSE9348, GSE20916, GSE8671, GSE5206, GSE6988, 
TCGA, PMID 12101425. Esophageal: GSE20347, 
GSE6059, GSE23400, GSE13898, GSE1420. Gastric: 
GSE27342, GSE13861, GSE13911, GSE19826, PMID 
12925757. Head and neck: GSE27155, GSE25099, 
GSE6631, GSE13601, GSE1722, GSE3524, GSE2379, 
GSE6791, GSE9844, GSE6004, GSE3467, GSE12452, 
PMID 12368205, PMID 15833835, PMID 14729608. 
Kidney: GSE15641, GSE4125, GSE11151, GSE2712, 
GSE14994, GSE6344, GSE781. Leukaemia: GSE2350, 
GSE13159, GSE2466, GSE7186, GSE1159, GSE28497, 
GSE1466, GSE995, GSE5788, PMID 16267031. Liver: 
GSE6764, GSE3500, GSE14520, GSE14323. Lung: 
GSE2514, GSE7670, GSE31210, GSE10072, GSE19188, 
GSE32863, GSE3398, GSE3268, PMID 11707567, 
PMID 15833835. Lymphoma: GSE6338, GSE2350, 
GSE3827, GSE1466, GSE12195, GSE14879, GSE12453. 
Melanoma: GSE7553, GSE3189, GSE6887, PMID 
15833814. Myeloma: GSE13591, GSE5900. Ovarian 
cancer: GSE6008, GSE26712, GSE12470, TCGA, PMID 
14760385, PMID 15161682. Pancreatic: GSE16515, 
GSE15471, GSE3654, GSE1542, PMID 16103885, PMID 
15867264, PMID 15548371. Prostate: E-TABM-26, 
GSE6099, GSE21034, GSE6956, GSE6919, GSE3325, 
GSE3933, PMID 12873976, PMID 19737960, PMID 
22722839, PMID14695335, PMID 11807955, PMID 
12086878, PMID 11507037, PMID 12154061. Sarcoma: 
GSE21122, GSE13861, GSE2719, GSE2712.
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